Brief: Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE (Trofinetide) For The Treatment Of Rett Syndrome
16/10/2024 21:08
Oct 16 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O :
* ACADIA PHARMACEUTICALS ANNOUNCES HEALTH CANADA APPROVAL OF
DAYBUE™ (TROFINETIDE) FOR THE TREATMENT OF RETT SYNDROME
Source text for Eikon: ID:nBw9H2D5Ra
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP